Hypervision Surgical Ltd is a spin-out company formed from King's College London and was founded by a team of clinicians, medical imaging and artificial intelligence (AI) experts. Based on safe light alone, our goal is to equip clinicians with advanced computer-assisted tissue analysis for improved surgical precision and patient safety.
Better intraoperative guidance can help reduce patient morbidity and healthcare costs across surgical specialties. For example, brain tumour patients undergoing surgery have significantly improved outcomes and increased life expectancy if complete tumour removal is achieved. However, maximal resection needs to be balanced with the goal of healthy tissue preservation in order to minimise patient risk and neurological impairment. Yet, even with the most advanced current techniques, intraoperative decisions with potentially life-changing consequences are still based on the surgeon’s subjective visual assessment.
Detailed real-time information increases surgical precision and patient safety
Intraoperative assessment requires a scale compatible with surgical action
Surgical workflow benefits from non-contact measurement approaches
Independence of exogenous contrast agents prevents side effects
Our approach is non-contact, non-invasive and does not require any exogenous contrast agent. We rely on the safe application of light alone.
Using AI, we provide quantitative, wide-field information on physiological tissue properties including perfusion assessment of tissue and blood vessels.
Our system is capable of AI-driven, wide-field tissue differentiation to identify tumour, normal tissue, nerves and blood vessels – in real time.
Hyperspectral imaging is a safe, non-contact and non-invasive optical imaging modality perfectly suited for the clinic. By splitting light into multiple spectral bands far beyond the conventional red/green/blue colours that the naked eye can see, hyperspectral imaging carries diagnostic information about tissue properties ideal for objective tissue characterisation.
With our strong expertise in interventional imaging, AI and medical devices, we have designed an intraoperative imaging system that seamlessly integrates into the surgical workflow and is capable of wide-field real-time data-driven tissue characterisation. This will objectively enhance the surgeon's ability to visualise and characterise tissue intraoperatively without injecting any contrast agents. In addition, we can monitor vital physiological tissue properties thereby increasing surgical precision and patient safety while optimising resection.
Further clinical studies are scheduled to develop and evaluate our technology to achieve commercial readiness.
GTC Sept 2022 Keynote with NVIDIA CEO Jensen Huang showcasing Hypervision Surgical during the ‘I am a visionary’ segment. The original keynote video is found here.
Hypervision Surgical, a London-based venture building an advanced surgical imaging and data analytics platform, announced the successful completion of an oversubscribed seed funding round, raising £6.5 million.
Read moreHypervision Surgical continues to attract new talent and welcomes its latest intern. Cameron Dockerill is a final-year MRC DTP PhD student at King’s College London.
Read moreThe four co-founders of Hypervison Surgical, a King’s College London spin-out company, have been awarded the Cutlers’ Surgical Prize for outstanding work in the field of instrumentation, innovation and technical development.
Read moreDefine and develop the software foundations of our product development
Design, implement, and validate new computational and machine learning frameworks
Join us for Research & Development, Regulatory, Clinical Validation, and Marketing internships
Don’t see something you like? At Hypervision Surgical we are always looking for ambitious and passionate people. Get in touch to see what opportunities there are available.
